Drug Profile


Alternative Names: Aptocine; Laserphyrin; Leserfin; Litx; LS 11; ME 2906; Mono-L-aspartyl chlorin e6; MR 901; NP e6; NPE 6; Talaporfin sodium; Taporfin sodium

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Light Sciences Oncology; Meiji Seika Pharma; The Childrens Hospital of Philadelphia
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma; Lung cancer; Oesophageal cancer
  • Phase II Benign prostatic hyperplasia
  • No development reported Cardiovascular disorders; Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Neurofibromatoses

Most Recent Events

  • 10 Jul 2017 Phase-II development for Benign prostatic hyperplasia is ongoing in USA (IV) (Light Sciences Oncology website, July 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 06 May 2015 No recent reports on development identified - Phase-I/II for Hepatocellular carcinoma in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top